Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA. A preliminary dose-finding cohort will be followed by 3 expansion cohorts.
Epistemonikos ID: 797909e50e7fbd808b082590935ddc3a27beb228
First added on: Jun 01, 2024